Procedures
tumor, death, toxicities, Tumors, Cancer
DISEASE PROGRESSION, TUMOR, ADVERSE EVENT, EVENT, DISEASE, TUMORS, CANCER
After enrollment, patient underwent up to six cycles of HAIC, each lasting 21 days, with the FOLFOX regimen. This regimen consisted of a 2-h infusion of oxaliplatin at 85 mg/mHAIC was performed by inserting a 5-French Yashiro catheter (Terumo Corporation, Tokyo, Japan) through the femoral artery with a 2.7-French microcatheter inside, and then, advancing the tip of the microcatheter to the tumor-feeding artery, guided by concurrent arteriography. Tumors were accessed via the right or left hepatic artery. When a tumor demonstrated additional blood supply from extrahepatic sources, catheter tip was positioned in the main feeding artery. Besides, branch arteries were embolized with blank microspheres. In the event that there is a short access path from intrahepatic arteries leading to chemical agents flowing into the gastroduodenal artery, coils would be used to embolize it. The administration of chemotherapeutic agents for HAIC was completed within 3 days after hepatic catheter placement. The catheter and sheath were removed after the completion of each HAIC.Combination therapy was discontinued when disease progression, disease downstaging to have an opportunity to perform curative treatment, unacceptable toxicities, or death occurred. In the event of grade ≥3 or serious TRAEs, the related study treatment should be discontinued, and the other two were allowed to continue.Every 6 weeks until treatment completion, tumor responses were evaluated using dynamic contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI), following both RECIST v1.1 and mRECIST criteria. In the event that a patient achieves complete response (CR) or partial response (PR), the response must be confirmed no less than 4 weeks of the initial evaluation. AEs during the treatment were recorded or graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) 4.0.